Albireo recognizes International Alagille Syndrome Awareness Day 2021

Albireo Pharma, Inc, a clinical-stage rare liver disease company developing novel bile acid modulators, today joins the Alagille community in commemorating the second annual International Alagille Syndrome Awareness Day on January 24, 2021 in honor of Dr. Daniel Alagille’s birthday. Alagille syndrome (ALGS) is a rare genetic disorder that can affect the liver, heart and other parts of the body. Albireo leaders reaffirm the Company’s commitment to advancing life-changing research and join the community in bringing greater awareness to patients and families affected by this rare and devastating disorder.

“Connecting with families who manage Alagille syndrome and hearing firsthand the burdens associated with the disease reaffirms our mission at Albireo, which is to provide hope and improve treatment options and outcomes for children and families with rare cholestatic liver diseases,” said Ron Cooper, President and Chief Executive Officer of Albireo. “Their feedback has been invaluable in helping design our Phase 3 study in Alagille syndrome, called ASSERT, which is currently enrolling eligible patients.”

Read the full press release here.